I agree…would be nice if NIH stepped up to the plate to include Leronlimab in the long COVID study; there is pretty strong overlap with the Phase 2 study Rector headed. Highly likely Leronlimab would move the needle for ME/CFS. Worth noting here there is also overlap with #2 priority HIV inflammation study. Per your linked article and referencing CRP as the primary endpoint for that prospective HIV study:

“Although inflammation is reflected in selective biomarkers, traditional inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate have also shown an increased trend in ME/CFS, particularly in those with mild/moderate disease generally not raised in ME/CFS.

All roads lead to the rabbit hole OHM went down with his research.